NCT04926454

Brief Summary

This study compares the efficacy of Dexmedetomidine as an adjuvant to Bupivacaine in Ultrasound Guided Transversus Abdominis Plane Block versus Caudal Block for post-operative analgesia in children undergoing congenital inguinal hernia repair especially to provide prolonged post-operative analgesia and decrease opioid consumption.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Sep 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 22, 2020

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

May 23, 2021

Completed
23 days until next milestone

First Posted

Study publicly available on registry

June 15, 2021

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 25, 2021

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2021

Completed
Last Updated

October 14, 2021

Status Verified

June 1, 2021

Enrollment Period

1.1 years

First QC Date

May 23, 2021

Last Update Submit

October 12, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • When Dexmedetomidine is administered in combination with local anesthetics in the epidural space, it has been shown to reduce postoperative analgesic requirements and have a significantly analgesic effect"

    The primary outcome measures were the time to first analgesia (in minutes from the time of caudal (or) TAP block injection to first registration of modified VAS scale ≥3 at any point of time will receive paracetamol 10mg/kg orally

    Within 24 hours post operative

Study Arms (2)

TAP block

EXPERIMENTAL

patients will receive general anesthesia followed by Tap block at the end of the operation.

Drug: Dexmedetomidine

Caudal block

EXPERIMENTAL

patients will receive general anesthesia followed by caudal block at the beginning of the operation.

Drug: Dexmedetomidine

Interventions

Patients will be monitored using standard monitoring (heart rate, non-invasive blood pressure, ECG and pulse oximetery) After the child is adequately anesthetized, intra-venous access with appropriate size cannula will be obtained Appropriate size LMA (2 and 2.5) will be inserted and patients will be allowed to breathe spontaneously. patients will receive 0.25% Bupivacaine (0.3ml/Kg) with 1 μg/kg dexmedetomidine After general anaesthesia

Also known as: Bupivacaine
Caudal blockTAP block

Eligibility Criteria

Age2 Years - 12 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • age 2-12 years
  • Elective congenital inguinal hernia repair operation under general anaesthesia.
  • Physical Status: ASA I and II Patients after taking written and informed consent from the parents or care giver.

You may not qualify if:

  • Refusal of procedure or participation in the study by parents.
  • Physical status: ASA III or above.
  • Children undergoing bilateral lower abdominal surgeries.
  • Infection at site of injection.
  • Congenital anomaly of the spine.
  • History of developmental delay, neurological disease, skeletal deformities.
  • History or evidence of coagulopathy.
  • Allergies to drugs used (Bupivacaine 0.5%)( dexmedetomidine/prcedex)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AinShams Hospitals

Cairo, 02, Egypt

RECRUITING

Related Links

MeSH Terms

Conditions

Pain, Postoperative

Interventions

DexmedetomidineBupivacaine

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Bahaa Eldeen Ewis, Professor

    Professor of Anesthesia, intensive care and pain management

    STUDY CHAIR

Central Study Contacts

Elsayed Mohamed Ali Mohamed, M.B.B.Ch

CONTACT

Mohamed Mohamed kamal, Lecturer

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 23, 2021

First Posted

June 15, 2021

Study Start

September 22, 2020

Primary Completion

October 25, 2021

Study Completion

October 30, 2021

Last Updated

October 14, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing
Will not share

Locations